Clinical Trial Update: Inhaled Treprostinil for PAH: Open-label Extension [Phase 3]

View source ↗

Summary

A Phase 3 open-label extension trial of inhaled treprostinil for pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Inhaled Treprostinil (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN